RE:RE:Ind ame results AH/ATE Great points being made on the Pfizer Tanezumab vote.
I found the company statement of the back end of the article (see below) to be interesting. Clearly Pfizer understands the large addressable market for pain relief on osteoarthritis.
TM
While we are disappointed with today’s outcome, we continue to believe that tanezumab has a positive benefit-risk profile for patients with moderate-to-severe osteoarthritis pain for whom current treatments are ineffective or not appropriate. Many of these patients have exhausted available therapies, have not had a new class of medications available to them in more than a decade and are eager for new, non-opioid options,” Ken Verburg, tanezumab development team leader at Pfizer Global Product Development said in a statement.